Last reviewed · How we verify
ABBV-2222
At a glance
| Generic name | ABBV-2222 |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis (PHASE2)
- A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 (PHASE2)
- A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABBV-2222 CI brief — competitive landscape report
- ABBV-2222 updates RSS · CI watch RSS
- AbbVie portfolio CI